Lupin Peer Comparison

NSE: LUPIN | BSE: 500257

₹2,025.00

₹28.00 (1.40%)

As on 09-Nov-2026IST

Market cap

₹92,007 Cr

Revenue (TTM)

₹30,746 Cr

P/E Ratio

17.7

P/B Ratio

3.8

Div. Yield

0.9 %

Edit

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Market cap (₹ Cr)	92,007	1,21,002	1,15,685	1,09,911	1,06,445
Revenue (₹ Cr)	30,746	30,378	33,097	15,379	36,913
Net Profit (₹ Cr)	5,221.47	4,159.00	2,759.70	2,249.69	3,993.05
Net Margin (%)	16.70	13.20	8.03	14.32	10.61
RoE (%)	24.24	16.61	7.30	13.86	10.51
Price to Earnings	17.67	28.95	41.32	49.01	26.68
Price-To-Book	3.83	4.35	2.98	6.25	2.70

Income Statement (₹ Cr)

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Operating Revenue	30,746.33	30,378.10	33,097.40	15,378.58	36,912.88
Total Income	31,258.85	31,504.60	34,352.50	15,705.47	37,650.01
Total Expenditure	21,504.94	22,828.30	28,236.90	11,301.83	29,349.95
EBITDA	9,241.39	7,549.80	4,860.50	4,076.75	7,562.93
Depreciation	1,698.50	2,027.20	2,141.40	907.11	1,961.27
EBIT	7,542.89	5,522.60	2,719.10	3,169.64	5,601.66
Interest	450.49	595.90	450.40	513.87	394.85
Other Income	512.52	1,126.50	1,255.10	326.89	737.13
Exceptional Items	-557.91	-499.30	0.00	-129.75	-105.51
Profit before Tax	7,047.01	5,553.90	3,523.80	2,852.91	5,838.43
Provision for Tax	1,825.54	1,394.90	764.10	603.22	1,845.38
Profit after Tax	5,221.47	4,159.00	2,759.70	2,249.69	3,993.05

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Shareholder's Funds	24,050.46	27,817.30	38,807.00	17,582.22	39,399.90
Minority Interest	-15.31	-101.90	40.20	-20.87	3.68
Non-Current Liabilities	3,318.63	7,260.60	3,074.90	5,214.33	2,689.12
Current Liabilities	12,541.26	18,023.50	15,430.30	5,884.79	19,667.17
Total Liabilities	38,146.06	50,672.60	56,576.70	27,754.83	58,196.15

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Non-Current Assets	14,387.96	36,142.90	26,891.10	20,096.89	26,331.59
Current Assets	23,070.16	18,433.50	29,732.20	7,956.27	33,958.66
Total Assets	38,146.06	50,672.60	56,576.70	27,754.83	58,196.15
Total Debt*	5,910.20	11,769.50	7,734.10	6,021.78	7,676.20
Net Current Assets	10,528.90	410.00	14,301.90	2,071.48	14,291.49
Contingent Liabilities	1,094.02	989.90	336.14	924.77	1,358.37

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Cash From Operating Activities	7,334.50	2,116.60	5,673.70	3,121.29	5,526.37
Cash Flow from Investing Activities	-3,864.59	-8,296.10	-6,549.30	-196.42	-3,458.61
Cash from Financing Activities	-845.87	5,806.90	829.00	-2,952.69	-1,269.15
Net Cash Inflow / Outflow	2,624.04	-372.60	-46.60	-27.82	798.61

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
ROCE (%)	28.86	21.39	13.75	13.24	12.76
ROE (%)	24.24	16.61	7.30	13.86	10.51
ROA (%)	14.23	8.11	4.93	7.79	6.99
EBIT Margin (%)	24.53	18.18	8.22	20.61	15.18
Net Margin (%)	16.70	13.20	8.03	14.32	10.61
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Revenue Growth (%)	24.22	24.02	-3.53	13.53	13.53
EBIT Growth (%)	38.02	-16.48	-58.47	31.59	13.09
Net Profit Growth (%)	20.10	-16.41	-51.77	27.79	15.82
EPS Growth (%)	30.16	-10.25	-51.50	34.22	19.29
Book Value Growth (%)	30.75	13.19	12.99	13.74	16.04

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Price / Earnings	16.32	26.66	41.29	46.79	26.32
Price / Book Value	3.83	4.35	2.98	6.25	2.70
Dividend Yield (%)	0.89	0.08	0.58	0.04	0.22
EV/EBITDA	9.60	16.63	23.95	27.94	13.69
Market Cap (₹ Cr)	1,05,737.27	87,643.18	1,04,763.81	82,801.75	75,689.14

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Debt to Equity	0.06	0.15	0.00	0.17	0.02
Short term debt to equity ratio	0.18	0.16	0.16	0.04	0.16
Current Ratio	1.84	1.02	1.93	1.35	1.73
Quick Ratio	1.32	0.64	1.40	0.95	1.06
Interest Coverage	16.64	10.32	8.82	6.55	15.79

	Lupin	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Debtors to sales (%)	21.65	14.42	30.64	14.17	20.44
Asset Turnover	0.84	0.59	0.59	0.53	0.65
Receivable days	51.23	33.55	103.79	39.93	33.71
Inventory Days	48.93	33.80	79.94	51.78	59.32
Payable days	205.75	149.82	84.78	111.46	148.20
Cash Conversion Cycle	-105.59	-82.46	98.95	-19.75	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.